Beam Therapeutics (BEAM) Highlights Progress Across Base Editing Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- Francis Halzen wins 2026 Nobel Prize in Physics
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
January 8, 2024 6:30 AM ESTFirst Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data Readout in Second Half of 2024
European Clinical Trial Application (CTA) Submitted for BEAM-302; Trial Initiation in Alpha-1 Antitrypsin Deficiency Planned for First Half of 2024
Investigational New Drug (IND) Application for BEAM-301 On-track for First Half of 2024
Cash Runway Expected to Support Operating Plans into 2027
CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) --... More



